Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Grand View Research | PRODUCT CODE: 1771707

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1771707

Onychomycosis Market Size, Share & Trends Analysis Report By Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis), By Treatment (Oral, Topical), By Region, And Segment Forecasts, 2025 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Onychomycosis Market Growth & Trends:

The global onychomycosis market size is anticipated to reach USD 5.74 billion by 2033, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 4.7% from 2025 to 2033. The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual's ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.

Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.

International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.

Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.

Onychomycosis Market Report Highlights:

  • Distal subungual onychomycosis segment dominated the market in 2024 and is attributable to the increasing prevalence and number of generic approvals by the FDA to meet the rising demands
  • Topical segment is expected to show the fastest growth rate over the forecast period owing to ease of usage and administration which leads to increased patient compliance with treatment
  • Players have an increased focus on acquiring specialized capacities that are highly capital-intensive to develop and maintain their competitive position
  • North America held the largest market share in 2024 which can be attributed to better access to healthcare, the presence of a wide target population, and high adoption of treatment
Show more
Product Code: GVR-4-68040-031-4

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Onychomycosis Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Onychomycosis Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Distal Subungual Onychomycosis
    • 4.4.1. Distal Subungual Onychomycosis Market, 2021 - 2033 (USD Million)
  • 4.5. White Superficial Onychomycosis
    • 4.5.1. White Superficial Onychomycosis Market, 2021 - 2033 (USD Million)
  • 4.6. Proximal Subungual Onychomycosis
    • 4.6.1. Proximal Subungual Onychomycosis Market, 2021 - 2033 (USD Million)
  • 4.7. Other Types
    • 4.7.1. Other Types Market, 2021 - 2033 (USD Million)

Chapter 5. Onychomycosis Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2025 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market, 2021 - 2033 (USD Million)
  • 5.5. Topical
    • 5.5.1. Topical Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Onychomycosis Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Onychomycosis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Onychomycosis Market Estimates and Forecasts, 2017 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Bausch Health Companies Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. GSK plc
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Abbott
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Pfizer Inc
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Bayer AG
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Teva Pharmaceutical Industries Ltd.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Cipla
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Merck & Co., Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Novartis AG
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sun Pharmaceutical Industries Ltd.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
Show more
Product Code: GVR-4-68040-031-4

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global onychomycosis market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 5 Global onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 6 North America onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 8 North America onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 9 U.S. onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 10 U.S. onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 11 Canada onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 12 Canada onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 13 Mexico onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 14 Mexico onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 15 Europe onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 17 Europe onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 18 UK onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 19 UK onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 20 Germany onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 21 Germany onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 22 France onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 23 France onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 24 Italy onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 25 Italy onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 26 Spain onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 27 Spain onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 28 Norway onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 29 Norway onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 30 Denmark onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 31 Denmark onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 32 Sweden onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 33 Sweden onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 37 Japan onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 38 Japan onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 39 China onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 40 China onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 41 India onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 42 India onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 43 Australia onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 44 Australia onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 45 South Korea onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 46 South Korea onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 47 Thailand onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 48 Thailand onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 49 Latin America onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 51 Latin America onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 52 Brazil onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 53 Brazil onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 54 Argentina onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 55 Argentina onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 59 South Africa onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 60 South Africa onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 63 UAE onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 64 UAE onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 65 Kuwait onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait onychomycosis market, by treatment, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Onychomycosis market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Onychomycosis market dynamics
  • Fig. 12 Onychomycosis market: Porter's five forces analysis
  • Fig. 13 Onychomycosis market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Distal Subungual Onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 16 White Superficial Onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 17 Proximal Subungual Onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 18 Other Types market, 2021 - 2033 (USD Million)
  • Fig. 19 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 20 Oral market, 2021 - 2033 (USD Million)
  • Fig. 21 Topical market, 2021 - 2033 (USD Million)
  • Fig. 22 Others market, 2021 - 2033 (USD Million)
  • Fig. 23 Onychomycosis market revenue, by region
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 North America onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. country dynamics
  • Fig. 27 U.S. onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 28 Canada country dynamics
  • Fig. 29 Canada onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 30 Mexico country dynamics
  • Fig. 31 Mexico onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 32 Europe onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 33 UK country dynamics
  • Fig. 34 UK onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 35 Germany country dynamics
  • Fig. 36 Germany onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 37 France country dynamics
  • Fig. 38 France onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 39 Italy country dynamics
  • Fig. 40 Italy onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 41 Spain country dynamics
  • Fig. 42 Spain onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 43 Norway country dynamics
  • Fig. 44 Norway onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 45 Sweden country dynamics
  • Fig. 46 Sweden onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 47 Denmark country dynamics
  • Fig. 48 Denmark onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan country dynamics
  • Fig. 51 Japan onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 52 China country dynamics
  • Fig. 53 China onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 54 India country dynamics
  • Fig. 55 India onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 56 Australia country dynamics
  • Fig. 57 Australia onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 58 South Korea country dynamics
  • Fig. 59 South Korea onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 60 Thailand country dynamics
  • Fig. 61 Thailand onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 62 Latin America onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 63 Brazil country dynamics
  • Fig. 64 Brazil onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 65 Argentina country dynamics
  • Fig. 66 Argentina onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 67 MEA onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 68 South Africa country dynamics
  • Fig. 69 South Africa onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 70 Saudi Arabia country dynamics
  • Fig. 71 Saudi Arabia onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 72 UAE country dynamics
  • Fig. 73 UAE onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 74 Kuwait country dynamics
  • Fig. 75 Kuwait onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 76 Company categorization
  • Fig. 77 Company market position analysis
  • Fig. 78 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!